Nvidia (NVDA) reached a rare buy point at $104 a share today. While we may see a retest, the price is now attractive enough to buy at least at least an initial entry. We bought a little more than half of our targeted allocation.
Daily Briefing: Nvidia (NVDA) reaches buying opportunity Read Post »
This post outlines how to approach our website and the best way to leverage our content to your advantage. We’ll update this post periodically overtime.
How to get the most out of Sam Weiss Read Post »
NASDAQ-100 getting dangerously close to transitioning into a double-correction. NVIDA hits a second instance of oversold conditions and nearing a buying opportunity. S&P 500 rejected off of its all-time highs.
Daily Briefing: Nvidia oversold, pull-back extends to 4% Read Post »
S&P 500 at breakout point, NASDAQ-100 still a bit murky, Nvida (NVDA) closing in on a near-term bottom and Apple ready to launch its Ai charged iPhone in a week.
September uncertainties loom ahead Read Post »
The NASDAQ-100 (QQQ) rally is on Day-7 which is on the high end of the range. If we don’t see the market resume its rally soon, this near-term pullback could metastasize.
Daily Briefing: Some uncertainty, with upside ahead Read Post »
We have a mixed bag today for both NVDA and the QQQ.
Daily Briefing: good news, Bad News day Read Post »
The QQQ pull-back has reached 3.4% which is exactly in-line with the historical trend. But with Nvidia reporting earnings today, the overall trend is at risk.
Daily Briefing: Wednesday, Aug 28, 2024 Read Post »
The NASDAQ-100 has formed a pretty substantial bull-flag on the hourly charts and is ready to breakout on the back of Nvidia (NVDA) earnings.
Daily Briefing: Tuesday, Aug 27, 2024 Read Post »
Covering intraday news, technicals and other highlights of the trading session for Monday, Aug 26, 2024.
Daily Briefing: Monday, Aug 26, 2024 Read Post »
While we expect the SPY, NASDAQ-100 and Dow to move higher in the coming weeks and months ahead, there are significant risks to our outlook that must be analyzed and reviewed.